Literature DB >> 11295051

Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells.

X Fan1, F B Furnari, W K Cavenee, J S Castresana.   

Abstract

The sensitivity of non-isotopic PCR-SSCP was compared to direct sequencing of PTEN exons. DNA from leukocytes derived from healthy donors, and from the glioblastoma cell line LN319 was extracted and mixed in different proportions from 0 to 100%. The LN319 cell line contains a point mutation at codon 15 exon 1 of the PTEN gene. The PCR-SSCP experiments demonstrated mutations in samples containing as little as 10% tumor DNA. In contrast, direct DNA sequencing experiments were less sensitive, requiring 30-70% of tumor DNA in the sample, depending on the DNA strand sequenced. In conclusion, PCR-SSCP, in our hands, is more sensitive than automated sequencing for detecting PTEN point mutations. We recommend to always sequence both strands, and take into account that samples containing less than 30% tumor cells should not only be sequenced, but also studied by PCR-SSCP in order to discriminate false negative results.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295051     DOI: 10.3892/ijo.18.5.1023

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  14 in total

1.  TP53 gene mutations are rare in nondysplastic Barrett's esophagus.

Authors:  Kamila Novotna; Marie Trkova; Alexandr Pazdro; Milan Smejkal; Alzbeta Soukupova; Daniela Kodetova; Premysl Smejkal; Zdenek Sedlacek
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

2.  Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer.

Authors:  Guo Jian; Zhou Songwen; Zhang Ling; Deng Qinfang; Zhang Jie; Tang Liang; Zhou Caicun
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-14       Impact factor: 4.553

Review 3.  Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.

Authors:  Xiaozhu Zhang; Alex Chang
Journal:  J Med Genet       Date:  2006-12-08       Impact factor: 6.318

4.  A mutation-sensitive switch assay to detect five clinically significant epidermal growth factor receptor mutations.

Authors:  Bin Liu; Lin Zhou; Qian Wang; Kai Li
Journal:  Genet Test Mol Biomarkers       Date:  2015-04-28

5.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

6.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  Arch Pathol Lab Med       Date:  2013-04-03       Impact factor: 5.534

7.  A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients.

Authors:  Yi Liu; Bing Liu; Xiao-Yan Li; Jian-Jie Li; Hai-Feng Qin; Chuan-Hao Tang; Wan-Feng Guo; Hai-Xu Hu; Sha Li; Cui-Jing Chen; Bing Liu; Hong-Jun Gao; Xiao-Qing Liu
Journal:  J Exp Clin Cancer Res       Date:  2011-12-06

8.  EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.

Authors:  H Kimura; Y Fujiwara; T Sone; H Kunitoh; T Tamura; K Kasahara; K Nishio
Journal:  Br J Cancer       Date:  2006-10-24       Impact factor: 7.640

9.  Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).

Authors:  H Kimura; M Suminoe; K Kasahara; T Sone; T Araya; S Tamori; F Koizumi; K Nishio; K Miyamoto; M Fujimura; S Nakao
Journal:  Br J Cancer       Date:  2007-09-17       Impact factor: 7.640

10.  Comparison of Epidermal Growth Factor Receptor Mutations between Metastatic Lymph Node Diagnosed by EBUS-TBNA and Primary Tumor in Non-Small Cell Lung Cancer.

Authors:  Hyo Jae Kang; Bin Hwangbo; Jin Soo Lee; Moon Soo Kim; Jong Mog Lee; Geon-Kook Lee
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.